Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

X-linked Hypophosphatemia (XLH) Clinical Trial

Official title:
An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Chinese Patients With X-linked Hypophosphatemic Rickets/Osteomalacia (XLH)

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Familial Hypophosphatemic Rickets
Hypophosphatemia
X-linked Hypophosphatemia (XLH)

Clinical Trial Details

NCT number	NCT04842032
Study type	Interventional
Source	Kyowa Kirin Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	November 1, 2021
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04842019` - Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH	Phase 4
Not yet recruiting	`NCT04872907` - Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT	Phase 3
Completed	`NCT04049877` - Retrospective and Prospective Disease Progression and Quality of Life in XLH
Completed	`NCT04188964` - Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age	Phase 1/Phase 2